Slide 1: Earnings Call – Q4 2021
Earnings Call – Q4 2021 February 24, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
2©2022 ViewRay Technologies, Inc. All rights reserved. This presentation has been prepared solely for use at this call and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires o
Slide 3: MRIdian Therapy Adoption Journey
3©2022 ViewRay Technologies, Inc. All rights reserved. Thousands of patients with clinically reported outcomes. MRIdian Therapy Adoption Journey Systems installed Patients Treated Then 3 Years Ago Now FY 2021 Growth 18k 48 4k 24 350% 100% First in innovation. First in patients. 1 As of December 31,
Slide 4: What We Achieved: FY 2021 financial results
4©2022 ViewRay Technologies, Inc. All rights reserved. What We Achieved FY 2021 financial results FY 2021 FY 2020 Change MRIdian orders 28 17 65% MRIdian backlog $313M $241M 30% Revenue $70M $57M 23%
Slide 5: Recent Clinical Data Event: Interim MIRAGE data signals superiority
5©2022 ViewRay Technologies, Inc. All rights reserved. 50% Recent Clinical Data Event Interim MIRAGE data signals superiority “In anticipation of the highly positive result implied by this interim analysis, we have now shifted to routinely offering MRI-guided SBRT at UCLA.” Amar Kishan, MD. Associat
Slide 6: What's next? Clinical data
6©2022 ViewRay Technologies, Inc. All rights reserved. What’s next? Clinical data Prostate Pancreas SCIMITAR March 10th @ ACRO Intended to demonstrate the feasibility of treating post-op prostate cancer with five fraction SBRT vs. the standard 6-7 weeks of radiation therapy. SMART Pancreas Mid-year
Slide 7: Newest Innovations: MRIdian A3i System
Newest Innovations MRIdian A3i System •Workflow efficiency ◦ Increase patient throughput ◦ Streamline adaptive workflow ◦ Integrate auto-contouring ◦ Remote, parallel workflow •Clinical utility ◦ Brain treatment package ◦ New imaging and planning scans ◦ 3D multiplanar tracking and automated beam ga
Slide 8: Financial Results Q4 & FY 2021
Financial Results Q4 & FY 2021
Slide 9: What We Achieved: FY & Q4 2021 financial results
9©2022 ViewRay Technologies, Inc. All rights reserved. FY 2021 Change Q4 2021 Change MRIdian orders 28 65% 7 40% MRIdian backlog $313M 30% Revenue $70M 23% $20M 10% Cash usage* $67M (4%) $7M 0% What We Achieved FY & Q4 2021 financial results (*) Excluding proceeds from equity offerings
Slide 10: What We Achieved: FY & Q4 2021 financial results
10©2022 ViewRay Technologies, Inc. All rights reserved. What We Achieved FY & Q4 2021 financial results FY 2021 Change Q4 2021 Change Revenue $70M 23% $20M_ 10% Gross profit $0.3M +$4M ($0.2M) -$0.3M Operating expense $104M 2% $29M_ 16% Cash usage* $67M (4%) $7M_ 0% Cash $218M 39% (*) Excluding proc
Slide 11: 2022 Guidance
11©2022 ViewRay Technologies, Inc. All rights reserved. FY 2 02 1 FY 2 02 2 G RO W TH % Revenue $84M - $104M $70M 20% - 48% (*) Excluding proceeds from equity offerings Cash usage $68M - $83M $67M* $1M - $16M Increase 2022 Guidance
Slide 12: ViewRay | Visibly Better
@ VIEW RAY |VISIBLY BETTER